The Methylenetetrahydrofolate Reductase C677T Polymorphism Does Not Associate with Susceptibility to Abdominal Aortic Aneurysm  by Jones, G.T. et al.
*Correspondi
Section of Sur
Zealand.
E-mail address
1078–5884/00The Methylenetetrahydrofolate Reductase C677T
Polymorphism Does Not Associate with Susceptibility to
Abdominal Aortic Aneurysm
G.T. Jones,* E.L. Harris, L.V. Phillips and A.M. van RijDepartment of Surgery, Dunedin School of Medicine, Otago University, Dunedin, New ZealandObjectives. To test whether the T variant of the C677T polymorphism in the gene for 5,10-methylenetetrahydrofolate
reductase (MTHFR) would associate with three distinct forms of vascular disease, abdominal aortic aneurysm (AAA),
coronary artery disease (CAD) and peripheral vascular disease (PVD).
Background. Increases in homocysteine induce elastolytic activity in the arterial wall, a condition which may favour
vascular pathogenesis including aneurysm formation. Homozygosity of the common T variant of the C677T polymorphism
in the gene for MTHFR has been shown to associate with increased levels of homocysteine. Thus, this functional
polymorphism may lead to an increased propensity to develop cardiovascular disease and, in particular, AAA.
Methods. An association study was conducted across 1207 subjects; 428 patients with AAA, 271 CAD patients, 226 PVD
patients and 282 controls being genotyped for the C667T variants of MTHFR.
Results. There were no significant differences in the frequency of the MTHFR C677T variant between any of the groups
examined. AAA patients who were homozygotes for the 677T allele did, however, appear to have significantly larger
aneurysms than C allele carriers.
Conclusion. This study provides no evidence that the T variant of MTHFR is associated with susceptibility to AAA, CAD
or PVD. It may, however, be a contributory factor in AAA severity as indicated by aneurysm size.Keywords: Genetics; Cardiovascular disease; 5,10-Methylenetetrahydrofolate reductase (MTHFR); Abdominal aortic
aneurysm; Peripheral vascular disease; Coronary artery disease.Introduction
Abdominal aortic aneurysm (AAA) afflicts a surpris-
ingly large portion of the older population, the
incidence increasing with smoking.1,2 Though many
exacerbating factors have been identified, the basic
cause of aneurysms is largely unknown but almost
undoubtedly multifactorial with contributions from
both environment and heredity. An increase in the
plasma level of the amino acid homocysteine (hyper-
homocysteinemia) is a common genetic condition
strongly influenced by diet.3 The association between
hyperhomocysteinemia and the development of ather-
osclerosis and coronary artery disease has become
well known.4–7
Destruction and degradation of the elastic layers of
the abdominal aorta is the sine qua non of AAA.
Recently, homocysteine was shown to induce theng author. Dr Greg Jones, Vascular Research Group,
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smooth muscle cells of the arterial vasculature.8 The
induction of EVE by homocysteine resulted in frag-
mentation of the internal elastic lamina and fraying
and splitting of muscle and elastic fibers of the media.
Thus, hyperhomocysteinemia may be a factor in the
development of aneurysms as well as atherosclerotic
occlusive disease.
A common C/T point mutation in nucleotide 677
of the gene for methylenetetrahydrofolate reductase
(MTHFR) converts an alanine to a valine in the protein
product of the gene.9 This results in a thermolabile
form of MTHFR and a consequent hyperhomocystei-
nemia, which can be normalized by a daily low-dose
supplement of folic acid.3 In recent years, much
evidence has accumulated implicating the C677T
variant of MTHFR as the most common cause of
hyperhomocysteinemia and linking it to a wide
variety of adverse cardiovascular effects.10,11 Recently,
the 667T allele of MTHFR has been found to associate
with abdominal aortic aneurysm in a Polish12 and in
an Italian13 population, though it should be noted thatEur J Vasc Endovasc Surg 30, 137–142 (2005)
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ered for genotype association analysis. Considering
that the 677T variant of MTHFR has been shown to
associate with increased levels of homocysteine and in
light of the research showing a possible association
between hyperhomocysteinemia and AAA, genomic
DNA from an Otago population previously character-
ized for AAA14,15 was genotyped for the 677T variant
of MTHFR to determine whether this common variant
would associate with AAA. For further comparison
and elucidation, the Otago coronary artery disease
(CAD) and peripheral vascular disease (PVD) popu-
lations were similarly genotyped.MethodsSubjects
The Otago population of AAA patients14 (nZ428) was
compared with patients with peripheral vascular
disease (PVD; nZ226), coronary artery disease
(CAD; nZ271) and a healthy control group (nZ282).
All patients provided written informed consent and
the study was undertaken with the approval and
oversight of the Otago Ethics Committee. All AAA
patients had aneurysms greater than 5 cm in diameter,
necessitating surgical repair. The largest single diam-
eter of the infrarenal aorta was measured by ultra-
sound and taken to be the size of the aneurysm. A
subset of 75 AAA patients (17.5%) had a family history
(one or more first-degree family members with an
AAA). PVD was defined as significant stenosis in
multiple segments, including clinical symptoms such
as claudication, rest pain, or tissue loss. Diagnosis was
further confirmed with a resting ankle-brachial index
less that 0.7, pulse volume recordings and arteriogra-
phy. CAD subjects all had angiographically proven
coronary artery stenosis R50% of the vessel internal
diameter in at least one vessel. Percent diameter
stenosis was visually estimated as the maximal
percent reduction in the vessel diameter expressed as
a percentage of the angiographically normal adjacent
vessel. The number of vessels involved (single, double
or triple) and the American College of Cardiology/
American Heart Association (ACC/AHA) classifi-
cation16 was used to evaluate the morphology of
coronary lesions at the index event.
Patients with PVD or CAD also underwent
abdominal ultrasound examination, to identify con-
current AAA and were excluded if maximum ante-
roposterior aortic diameter was greater than 2.5 cm.
Control subjects were recruited from local communityEur J Vasc Endovasc Surg Vol 30, August 2005groups, with inclusion criteria of age greater than 55
years, no history of ischemic heart disease and being
currently in good general health.
All subjects were given a questionnaire to ascertain
demographic risk factors. Information collected
included age, gender, history of hypertension, hyper-
lipidemia, diabetes (type collected but grouped for
analysis), stroke, ischemic heart disease and PVD.
Smoking habits (current and past) were assessed, and
the number of pack-years was calculated (1 pack-year
equalled 20 cigarettes per day for 1 year). Plasma
samples were also collected, and lipoprotein A (Lp(a))
levels were analyzed with sandwich enzyme-linked
immunosorbent assay.PCR genotyping
Genomic DNA was extracted from blood samples
using a modified salting out procedure, and diluted to
50 ng/ml. PCR primers were designed using Primer-
Select (DNASTAR, Inc.) applied to template sequence
GenBank accession number AF105980 which contains
exon 4 of the MTHFR gene and partial sequences of
introns 3 and 4. The C677T single nucleotide poly-
morphism (SNP) reported in the first paper to observe
its effect17 is at base 129 in AF105980. The AGG-
GAGCTTTGAGGCTGACCTGAA (C) and
GGGGACGATGGGGCAAGTGAT (K) primers
amplify a 151 bp-fragment. The restriction enzyme
HinfI (New England Biolab, Inc., MA, USA) recognises
and cuts a GATTC sequence. T allele (underlined)
carriers have this sequence and are, therefore, cut into
51 and 100-bp fragments. Alternatively, the equivalent
region in C allele carriers has a GATCC sequence
which is not recognised by HinfI and the PCR product
is, therefore, left intact. Subsequent to PCR amplifica-
tion,HinfI digestion and electrophoresis in 1! TAE on
3% Seakem LE agarose gels (BMA Products, Rockland,
ME, USA), the fragments from patients and controls
were detected by ethidium bromide staining (Fig. 1).Statistical analysis
Statistical analysis was performed using StatView
version 5.01 (SAS Institute Inc.). Genotype and allele
frequencies were compared using chi-squared tests.
For continuous variables ANOVAwith Fisher’s PLSD
test were performed. Multiple logistic regression was
used to test interactive effects of variables. A p value
less than 0.05 was considered significant and all data is
presented as meansGone standard deviation.
Fig. 1. Ethidium bromide stained agarose gel of MTHFR
C677T genotype products. The 151 bp PCR product was
digested with HinfI. Sequences with a C allele at the 677
polymorphic site were not digested by this restriction
enzyme (undigested 151 bp fragment) while those with a T
allele were cleaved into two fragments (101 bp fragment
visible on gel). Lanes (left to right): a C allele homozygote
(CC), a heterozygote (CT) and a T allele homozygote (TT).
The last lane contains a 100 bp DNA ladder with band sizes
indicated.
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The frequencies of the common C and rarer T alleles
were comparable among all four populations exam-
ined (Table 1) and were also similar those reported in
other Caucasians populations.11 There were no sig-
nificant differences in the frequency of the T allele or
the T homozygote genotype between the control group
and the AAA, CAD and PVD patient populations
(Table 1). In accord with this finding, the distribution
of genotypes was comparable among all populations
(c2 p value for trend 0.78). All genotypes were in
Hardy–Weinburg equilibrium with predicted versus
actual genotype c2 p values of: controls 0.98, AAA 0.41,
CAD 0.61, PVD 0.55.
The familial AAA subgroup had a T allele
frequency of 0.29 with 9.3% being T homozygotes,
neither being significantly different from either the
control or other vascular disease groups. In the
coronary artery disease group, there was no associ-
ation between either T allele frequency or TTable 1. MTHFR C677T genotype and allele frequencies in control, A
Controls (nZ282) AAA (nZ428
C homozygote 47.5 49.1
CT heterozygote 43.3 39.5
T homozygote 9.2 11.4
C allele 0.692 0.688
T allele 0.308 0.312
MTHFR C677T genotype, expressed as percentages of each population
genotype (c2 test, pZ0.78) frequency between any of the groups examhomozygotes and the severity of CAD, as assessed
by either the number of vessels containing significant
stenoses (pZ0.87) or the index ACC/AHA lesion
severity scores (pZ0.68). Similarly, this polymorphism
did not associate with severity of peripheral vascular
disease as indicated by ankle brachial index (pZ0.32).
There were no obvious associations observed between
this polymorphism and any of the demographic
characteristics assessed including age, gender, body
mass index, waist circumference or waist–hip ratio.
There were, however, significant differences in the
demographic risk factor profiles of the four groups
examined (Table 2). Using multiple logistic regression
to test for these potentially interactive effects a model
which accounted for age, gender, non-fasting trigly-
cerides, HDL, Lp(a), smoking pack years, history of
hypertension and hypercholesterolemia was applied
using the control population and the common C
homozygote genotype as references. The resulting
adjusted odds ratios and 95% confidence intervals for
an association between the T homozygote genotype
and disease groups were 1.12 (0.56–2.22, pZ0.76) for
AAA, 1.81 (0.83–3.93, pZ0.13) for CAD and 0.90 (0.34–
2.35, pZ0.83) for PVD.
Interestingly, abdominal aortic aneurysm diameter
at time of diagnosis was significantly greater in T
homozygotes compared to C allele carriers (6.6G1.9
versus 6.0G1.6 cm, pZ0.037). The resulting odds ratio
for T homozygotes and aneurysm size was 1.35 (1.05–
1.72, p!0.02) after adjusting for age, gender, non-
fasting triglycerides, HDL, smoking pack years,
diabetes, history of hypertension and hypercholester-
olemia. There was no such association between the
MTHFR C677T genotype and abdominal aortic diam-
eter in either the CAD or PVD patient groups
examined.Discussion
The allele frequencies of the C677T variants of MTHFR
differ widely among populations around the world,
and there is even a distinct gradient within Europe, the
proportion of the T allele increasing from North toAA, CAD and PVD populations
) CAD (nZ271) PVD (nZ226)
50.5 46.8
38.4 39.8
11.1 13.4
0.697 0.668
0.303 0.332
and allele frequencies. There was no significant difference in allele or
ined.
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Table 2. Demographic characteristics of the control, AAA, CAD and PVD populations
Controls (nZ282) AAA (nZ428) CAD (nZ271) PVD (nZ226)
Gender (%male) 42.6 77.8* 72.3* 57.8*†
Age (years) 69.5G7.6 71.7G7.6* 64.0G9.5* 71.6G 9.1*
Hypertension (%) 25.9 55.5* 51.0*§ 66.1*‡
Hypercholesterolemia
(%)
16.3 30.6*s 52.8*¶ 41.0*
Diabetes (%) 8.2 5.9** 21.8* 23.7*
Smoking (pack years) 11.3G19.4 30.3G29.6* 18.8G24.3*†† 30.7G34.9*
Triglycerides (mmol/l) 2.1G1.0 2.3G1.2* 2.2G1.3 2.5G1.2*
Lp(a) (nmol/l) 43.9G61.6 64.5G90.5* 76.2G95.6* 74.6G95.1*
Cardiovascular demographic risk factors were not only associated with all three forms of atherosclerotic disease but also showed differential
association between disease groups. Most notable was the absence of association between diabetes and AAA. *p!0.001 versus controls. †p!
0.0001 versus AAA. ‡p!0.005 versus AAA or CAD. §p!0.005 versus AAA. sp!0.005 versus CAD or PVD. ¶p!0.05 versus PVD. **p!0.0001
versus CAD or PVD. ††p!0.0001 versus AAA or PVD.
G. T. Jones et al.140South.18 However, the allele frequencies of the C677T
variants in our study subject populations were in
accord with those typical in European populations.11
Most importantly, there were no significant differences
in C677T allele frequencies or zygosities among all
four populations we studied; AAA, CAD, PVD and
controls.
The T variant of the C677T functional SNP in the
gene for MTHFR is the most common cause of genetic
hyperhomocysteinemia.9,19 Several small studies have
found an association between the incidence of AAA
and both the frequency of the MTHFR 677T allele12,13
and circulating levels of homocysteine.10,13 These
observations appear consistent with reports linking
increased homocysteine with risk of cardiovascular
disease.4,6,10 Hyperhomocysteinemia has been specifi-
cally associated with PVD,10,20 CAD,6,21,22 as well as
with AAA.10,13 Thus, we anticipated possible associ-
ations between the Tallele of C677Tand all three of the
phenotypically distinct vascular disease groups exam-
ined in this study. It is sometimes the case that
associations fail to reach significance because the
study population is too small. This may well account
for our negative observations in both the CAD and
PVD groups. However, at 428, our AAA population is
the largest tested, to date, for association with the
MTHFR 677Tallele. In contrast, Brunelli et al.13 studied
only 58 AAA patients and Strauss et al.12 studied 63. It
is clear that the relationship between hyperhomocys-
teinemia and vascular disease is complex and multi-
factorial with influences from both environment and
genetics, thus making it difficult to pinpoint the basis
of the apparent divergence between this study and the
previously reported positive associations.12,13 For
example, variation in allele frequency due to ethni-
city18 cannot be excluded as a confounding factor.
Nevertheless, the most probable explanation for the
failure of this study to corroborate an association
betweenMTHFR C677T genotype frequency and AAA
is the underpowered nature of the previous studies.Eur J Vasc Endovasc Surg Vol 30, August 2005It is worth noting that while we did not see an
association between this MTHFR polymorphism and
apparent susceptibility to AAA there did appear to be
an association between this genetic variant and
aneurysm size. This effect persisted after correction
for possible confounders including age and gender.
While this study was not specifically designed to
examine this relationship, it appears to be consistent
with that reported by Brunelli and co-workers13 in
which they noted that hyperhomocysteinemic AAA
patients had significantly larger aneurysms compared
to those with normal homocysteine levels (5.09G0.84
versus 5.79G1.5 cm; p!0.05). The aneurysms
observed in this study were significantly larger than
those reported by Brunelli et al., with the previous
study clearly including a significant proportion of
subjects with aortic diameters less than 5 cm. The vast
majority of aneurysms in this current study, while
being of a size suitable for surgery, were detected
incidentally at routine examination or as a result of
investigations for other problems and were, therefore,
without obvious selection bias. If the association
between the MTHFR 677T allele and aneurysm size
is borne out, in appropriately designed aneurysm
growth surveillance studies, such data would suggest
that this allele is influential in the expansion process
rather than in the events initiating AAA.
With regard to potential environmental confoun-
ders, dietary supplementation with folate ameliorates
increases in plasma homocysteine in MTHFR 677T
homozygotes. Individuals homozygous for the T
variant of MTHFR require around 400 mg per day of
folic acid (in addition to their usual dietary folate
intake) to achieve homocysteine levels comparable
with the other genotypes.3 It is highly unlikely that
people living in NZ would have been receiving 400 mg
folic acid in their diets unless they were supplement
users. Some foods (mainly breakfast cereals) are
voluntarily fortified to provide 100 mg folic acid per
serve. Studies of Otago residents, the region from
The MTHFR 677T Allele Does Not Associate with AAA Susceptibility 141which over 90% the subjects genotyped in this study
were recruited, indicate that, based on changes in red
blood cell folate concentrations, the average consump-
tion of folic acid is approximately 100 mg per day
(personal communication with Dr Bernard Venn,
Department of Human Nutrition, University of
Otago). Thus, it is unlikely that any impact of the T
allele has been reduced by dietary folate consumption
in the Otago populations we studied.
A limitation of this study is that control subjects,
unlike CAD or PVD patients, were not screened for
AAA. Screening studies indicate that less than 5% of
our control group is likely to have a AAA (O3 cm),
with less than 0.5% (of men) being expected to have a
surgical (O5 cm) aneurysm equivalent to the AAA
patients examined in this study.1 This would, there-
fore, correspond to only one or two subjects and it is
highly improbable that such ‘contamination’ by
asymptomatic AAA’s could represent a major con-
founder. Moreover, the CAD and PVD groups were
screened to exclude AAA and there was no difference
in MTHFR genotypes between these groups.
The relationships between hyperhomocysteinemia
and vascular disease appear well established with
many papers supporting a causal association between
increases in plasma homocysteine and cardiovascular
pathology since the initial observation in 1969.4
Though there have also been negative results reported,
meta-analysis indicates that there is a likely associ-
ation between homocysteine and cardiovascular dis-
ease risk,21–23 though the exact size of this effect
remains unclear. Thus, the debate continues as to
whether hyperhomocyteinemia is the direct under-
lying cause of vascular disease or whether it merely
serves as a marker for some occult pathophysiology. A
recent study strongly suggests methionine is the real
culprit in vascular diseases associated with hyperho-
mocysteinemia.24 It appears that some product of
excess methionine metabolism rather than high
plasma homocysteine may underlie the association of
homocysteine with cardiovascular disease. Betaine-
homocysteine methyltransferase (BHMT) is involved
with the remethylation of homocysteine into methion-
ine. To date, however, none of the polymorphisms
identified in the coding regions of this gene have been
linked with changes in homocysteine levels25 and
linkage analysis has failed to show any association
between the BHMT gene and AAA.26 BHMT poly-
morphisms were, therefore, not examined in this
present investigation.
In conclusion, we found no significant association
with the frequency of the T allele of the C677T SNP in
the MTHFR gene or TT homozygosity and any of the
distinct vascular disease phenotypes examined,abdominal aortic aneurysm, coronary artery disease
and peripheral artery disease.Acknowledgements
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